-+ 0.00%
-+ 0.00%
-+ 0.00%
Ackermans & van Haaren leads USD 60 million seed round for Commit Biologics
Share
Listen to the news
Ackermans & van Haaren leads USD 60 million seed round for Commit Biologics
  • Ackermans & van Haaren led the final close of Commit Biologics' USD 60 million seed financing round.
  • Through AvH Growth Capital, it will conditionally invest up to EUR 10.5 million in tranches, acquiring an initial 10.2% stake.
  • Denmark-based Commit Biologics develops complement-engaging therapies for selective immune cell depletion in cancer and autoimmune diseases.
  • New investors AbbVie Ventures and M Ventures participated alongside existing investors.
  • Proceeds will fund COM002's investigational new drug application activities, advance a second program into IND-enabling development and expand the pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ackermans & van Haaren NV published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending